Eli Lilly director Sulzberger acquires 3.9976 shares
Eli Lilly & Co. director Gabrielle Sulzberger acquired 3.9976 shares of common stock on October 19, 2026, at a reported price of $1,240.34 per share.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Eli Lilly & Co. director Gabrielle Sulzberger acquired 3.9976 shares of common stock on October 19, 2026, at a reported price of $1,240.34 per share. At her election, the shares were deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following her separation from service. Her reported direct holdings after the transaction were 3,016.4449 shares.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock F1 | 3.9976 | $1,240.34 | $5K |
Footnotes (1)
- F1. At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service.
Key Figures
Key Terms
Lilly Directors' Deferral Plan financial
stock units financial
separation from service financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When will Gabrielle Sulzberger's LLY stock units be settled?
AI-generated analysis. How Rhea-AI works. Not financial advice.